Advancing Care in Neuroendocrine Carcinomas: From Disease Burden to Emerging Therapeutic Frontiers
EP. 1: Understanding Neuroendocrine Carcinomas: Definitions, Types, and Clinical Presentation
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Experts unpack neuroendocrine carcinoma vs tumors, key pathology markers, and high-risk features shaping prognosis and treatment decisions.
EP. 2: The Diagnostic Journey in Extrapulmonary Neuroendocrine Carcinoma: Team-Based Care and Classification
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Learn how rare neuroendocrine cancers are diagnosed, why pathology and Ki-67 guide care, and how teams coordinate chemo, trials, support.
EP. 3: Closing the Gap: Underrecognition and the Critical Need for Early Diagnosis in Extrapulmonary Neuroendocrine Carcinoma
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Rare neuroendocrine carcinomas outside the lung often go missed; expert pathology and rapid referrals enable earlier treatment and better outcomes.
EP. 4: Navigating the Human Side of Extrapulmonary Neuroendocrine Carcinoma: Patient Burden and Caregiver Support
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Experts warn extrapulmonary neuroendocrine carcinomas are often missed; faster pathology, rapid referrals, and early treatment improve survival.
EP. 5: Current Treatments and Biomarker Testing in Extrapulmonary Neuroendocrine Carcinoma: Strengths, Limitations, and Clinical Relevance
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Learn how aggressive neuroendocrine carcinoma disrupts daily life—and why rapid treatment, strong caregiver support, and navigation resources matter.
EP. 6: Guidelines, Infrastructure, and Stakeholder Roles in Biomarker Testing for Extrapulmonary Neuroendocrine Carcinoma
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Experts explain evolving biomarker testing for rare neuroendocrine carcinomas, from NCCN gaps to DLL3 and NGS, guiding trials and treatment.
EP. 7: Clinical Pathways, Barriers, and Infrastructure Needs in Biomarker Testing for Extrapulmonary Neuroendocrine Carcinoma
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Explore evolving biomarker testing for rare neuroendocrine carcinomas—NGS, MSI/TMB, and emerging DLL3 targets guiding new trials.
EP. 8: Access and Adherence: Navigating Insurance Coverage and Real-World Barriers to Biomarker Testing in Extrapulmonary Neuroendocrine Carcinoma
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Learn how tumor and liquid biopsy testing fits care—plus insurance hurdles, turnaround delays, and the push for faster NGS results.
EP. 9: Unmet Needs and Emerging Mechanisms of Action in Extrapulmonary Neuroendocrine Carcinoma: The Path Toward Better Therapies
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Learn how tumor and liquid biopsy biomarker tests are ordered, why results take weeks, and how insurance rules can delay cancer treatment.
EP. 10: Emerging Data and the Future Treatment Landscape in Extrapulmonary Neuroendocrine Carcinoma: Novel Therapies, Algorithms, and Combination Strategies
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD This episode, titled ‘Emerging Data and the Future Treatment Landscape in Extrapulmonary Neuroendocrine Carcinoma: Novel Therapies, Algorithms, and Combination Strategies,’ featured panelists discussing the following critical questions
EP. 11: The Road Ahead: Personalized Therapy, Combination Approaches, and Key Takeaways in Extrapulmonary Neuroendocrine Carcinoma
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Experts outline evolving EP-NEC care: smarter combo therapies, DLL3 targets, precise pathology, and why early clinical trials matter.
